Alloy Announces New Licensing Model for Discovery Platform

Alloy Therapeutics, a biotechnology ecosystem company focused on democratizing access to advanced drug discovery technologies, announced the launch of a new, market-disrupting licensing structure. Partners now have the option to utilize the ATX-Gx™ antibody technology platform without annual access fees or development milestones, benefiting from Alloy’s position as a continually expanding source of pre-competitive, foundational discovery technologies.

Since its launch in 2019, the ATX-Gx platform has become a leading industry standard in fully human transgenic mouse technology, with over 170 partners, more than 65 partnered programs, and 10 therapeutic leads currently in clinical development. Committed to reinvesting revenue into innovation, Alloy has expanded its murine platforms to include new strains.

Learn more